Evidence map›Paper›PMID 39529490›Full record

GuidelineJournal of diabetes investigation2025

Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English version).

Akira Shimada, Eiji Kawasaki, Norio Abiru, Takuya Awata, Yoichi Oikawa, Haruhiko Osawa, Hiroshi Kajio, Junji Kozawa, Kazuma Takahashi, Daisuke Chujo and 7 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Update on slowly progressive type 1 diabetes.Journal of diabetes investigation · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Akira ShimadaDepartment of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan.ORCID https://orcid.org/0000-0002-3954-4983
Eiji KawasakiDiabetes Center, Shin-Koga Hospital, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-7434-4744
Norio AbiruMidori Clinic, Nagasaki, Japan.
Takuya AwataDiabetes Research Center, National Center for Global Health and Medicine, Tokyo, Japan.
Yoichi OikawaDepartment of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan.ORCID https://orcid.org/0000-0003-1524-6751
Haruhiko OsawaDepartment of Diabetology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Hiroshi KajioDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
Junji KozawaEndowed Department of Diabetes Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0001-9665-8947
Kazuma TakahashiSchool of Nursing, Iwate Prefectural University, Takizawa, Iwate, Japan.
Daisuke ChujoCenter for Clinical Research, Toyama University Hospital, Toyama, Japan.
Shinsuke NosoDepartment of Endocrinology, Metabolism and Diabetes, Kindai University Faculty of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0002-0943-8450
Tomoyasu FukuiDivision of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Showa University, Tokyo, Japan.
Junnosuke MiuraDivision of Diabetes and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5115-1111
Kazuki YasudaDepartment of Diabetes, Endocrinology and Metabolism, Kyorin University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-6966-496X
Hisafumi YasudaDivision of Health Sciences, Department of Public Health, Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan.
Akihisa ImagawaDepartment of Internal Medicine (I), Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.ORCID https://orcid.org/0000-0002-4213-3229
Hiroshi IkegamiDepartment of Endocrinology, Metabolism and Diabetes, Kindai University Faculty of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0001-8808-4605

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin treatment should be introduced in patients with slowly progressive type 1 diabetes (SPIDDM; definite), according to the revised diagnostic criteria of SPIDDM (2023). In contrast, SPIDDM (probable) patients are in a non-insulin-dependent state; therefore, a more flexible treatment can be considered, although sulfonylurea agents should be avoided. Insulin treatment has been shown to maintain endogenous insulin secretion capacity in SPIDDM (probable); however, this does not mean that all SPIDDM (probable) patients should use insulin from the early phase. Dipeptidyl peptidase-4 inhibitors and biguanides might be the treatment of choice for SPIDDM (probable), but no evidence exists for other hypoglycemic agents. In any case, careful monitoring of the endogenous insulin secretion capacity should be carried out, and if a decrease in insulin secretion capacity is suspected, a change in treatment should be considered to prevent progression to an insulin-dependent state.

Indexed as

Diabetes Mellitus, Type 1Disease ProgressionHypoglycemic AgentsInsulinDipeptidyl-Peptidase IV InhibitorsHumansDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsInsulinHypoglycemic drugsInsulin‐independent stateSlowly progressive insulin‐dependent diabetes

Identifiers

PMID39529490
PMCPMC11693580

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.